An updated list of eumycetoma causative agents and their differences in grain formation and treatment response
Clin Microbiol Rev. 2024 May 1:e0003423. doi: 10.1128/cmr.00034-23. Online ahead of print.ABSTRACTSUMMARYIn 2023, the World Health Organization designated eumycetoma causative agents as high-priority pathogens on its list of fungal priority pathogens. Despite this recognition, a comprehensive understanding of these causative agents is lacking, and potential variations in clinical manifestations or therapeutic responses remain unclear. In this review, 12,379 eumycetoma cases were reviewed. In total, 69 different fungal species were identified as causative agents. However, some were only identified once, and there was no sup...
Source: Clinical Microbiology Reviews - May 1, 2024 Category: Microbiology Authors: Wendy W J van de Sande Ahmed H Fahal Source Type: research
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response
Clin Microbiol Rev. 2024 May 1:e0003423. doi: 10.1128/cmr.00034-23. Online ahead of print.ABSTRACTSUMMARYIn 2023, the World Health Organization designated eumycetoma causative agents as high-priority pathogens on its list of fungal priority pathogens. Despite this recognition, a comprehensive understanding of these causative agents is lacking, and potential variations in clinical manifestations or therapeutic responses remain unclear. In this review, 12,379 eumycetoma cases were reviewed. In total, 69 different fungal species were identified as causative agents. However, some were only identified once, and there was no sup...
Source: Clinical Microbiology Reviews - May 1, 2024 Category: Microbiology Authors: Wendy W J van de Sande Ahmed H Fahal Source Type: research
An updated list of eumycetoma causative agents and their differences in grain formation and treatment response
Clin Microbiol Rev. 2024 May 1:e0003423. doi: 10.1128/cmr.00034-23. Online ahead of print.ABSTRACTSUMMARYIn 2023, the World Health Organization designated eumycetoma causative agents as high-priority pathogens on its list of fungal priority pathogens. Despite this recognition, a comprehensive understanding of these causative agents is lacking, and potential variations in clinical manifestations or therapeutic responses remain unclear. In this review, 12,379 eumycetoma cases were reviewed. In total, 69 different fungal species were identified as causative agents. However, some were only identified once, and there was no sup...
Source: Clinical Microbiology Reviews - May 1, 2024 Category: Microbiology Authors: Wendy W J van de Sande Ahmed H Fahal Source Type: research
Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Clin Microbiol Rev. 2024 Apr 30:e0015222. doi: 10.1128/cmr.00152-22. Online ahead of print.ABSTRACTSUMMARYThe human immunodeficiency virus (HIV) epidemic remains a formidable global health concern, with 39 million people living with the virus and 1.3 million new infections reported in 2022. Despite anti-retroviral therapy's effectiveness in pre-exposure prophylaxis, its global adoption is limited. Broadly neutralizing antibodies (bNAbs) offer an alternative strategy for HIV prevention through passive immunization. Historically, passive immunization has been efficacious in the treatment of various diseases ranging from onco...
Source: Clinical Microbiology Reviews - April 30, 2024 Category: Microbiology Authors: Sharana Mahomed Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Vaccines and monoclonal antibodies: new tools for malaria control
Clin Microbiol Rev. 2024 Apr 24:e0007123. doi: 10.1128/cmr.00071-23. Online ahead of print.ABSTRACTSUMMARYMalaria remains one of the biggest health problems in the world. While significant reductions in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend has stalled, rather significant increases in malaria cases are seen in multiple areas. In 2022, there were 249 million estimated cases, and 608,000 malaria-related deaths, mostly in infants and children aged under 5 years, globally. Therefore, in addition to the expansion of existing anti-malarial control measures, it is critical to dev...
Source: Clinical Microbiology Reviews - April 24, 2024 Category: Microbiology Authors: Kazutoyo Miura Yevel Flores-Garcia Carole A Long Fidel Zavala Source Type: research
Recent development and fighting strategies for lincosamide antibiotic resistance
Clin Microbiol Rev. 2024 Apr 18:e0016123. doi: 10.1128/cmr.00161-23. Online ahead of print.ABSTRACTSUMMARYLincosamides constitute an important class of antibiotics used against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus. However, due to the misuse of lincosamide and co-selection pressure, the resistance to lincosamide has become a serious concern. It is urgently needed to carefully understand the phenomenon and mechanism of lincosamide resistance to effectively prevent and control lincosamide resistance. To date, six mobile lincosamide resistance classes, including lnu, cfr, erm, vga, ...
Source: Clinical Microbiology Reviews - April 18, 2024 Category: Microbiology Authors: Yingying Yang Shiyu Xie Fangjing He Yindi Xu Zhifang Wang Awais Ihsan Xu Wang Source Type: research
Recent development and fighting strategies for lincosamide antibiotic resistance
Clin Microbiol Rev. 2024 Apr 18:e0016123. doi: 10.1128/cmr.00161-23. Online ahead of print.ABSTRACTSUMMARYLincosamides constitute an important class of antibiotics used against a wide range of pathogens, including methicillin-resistant Staphylococcus aureus. However, due to the misuse of lincosamide and co-selection pressure, the resistance to lincosamide has become a serious concern. It is urgently needed to carefully understand the phenomenon and mechanism of lincosamide resistance to effectively prevent and control lincosamide resistance. To date, six mobile lincosamide resistance classes, including lnu, cfr, erm, vga, ...
Source: Clinical Microbiology Reviews - April 18, 2024 Category: Microbiology Authors: Yingying Yang Shiyu Xie Fangjing He Yindi Xu Zhifang Wang Awais Ihsan Xu Wang Source Type: research
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Clin Microbiol Rev. 2024 Apr 11:e0007423. doi: 10.1128/cmr.00074-23. Online ahead of print.ABSTRACTSUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, ...
Source: Clinical Microbiology Reviews - April 11, 2024 Category: Microbiology Authors: Martin Hoenigl Amir Arastehfar Maiken Cavling Arendrup Roger Br üggemann Agostinho Carvalho Tom Chiller Sharon Chen Matthias Egger Simon Feys Jean-Pierre Gangneux Jeremy A W Gold Andreas H Groll Jannes Heylen Jeffrey D Jenks Robert Krause Katrien Lagrou Source Type: research
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Clin Microbiol Rev. 2024 Apr 11:e0007423. doi: 10.1128/cmr.00074-23. Online ahead of print.ABSTRACTSUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, ...
Source: Clinical Microbiology Reviews - April 11, 2024 Category: Microbiology Authors: Martin Hoenigl Amir Arastehfar Maiken Cavling Arendrup Roger Br üggemann Agostinho Carvalho Tom Chiller Sharon Chen Matthias Egger Simon Feys Jean-Pierre Gangneux Jeremy A W Gold Andreas H Groll Jannes Heylen Jeffrey D Jenks Robert Krause Katrien Lagrou Source Type: research
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease
Clin Microbiol Rev. 2024 Apr 11:e0007423. doi: 10.1128/cmr.00074-23. Online ahead of print.ABSTRACTSUMMARYFungal infections are on the rise, driven by a growing population at risk and climate change. Currently available antifungals include only five classes, and their utility and efficacy in antifungal treatment are limited by one or more of innate or acquired resistance in some fungi, poor penetration into "sequestered" sites, and agent-specific side effect which require frequent patient reassessment and monitoring. Agents with novel mechanisms, favorable pharmacokinetic (PK) profiles including good oral bioavailability, ...
Source: Clinical Microbiology Reviews - April 11, 2024 Category: Microbiology Authors: Martin Hoenigl Amir Arastehfar Maiken Cavling Arendrup Roger Br üggemann Agostinho Carvalho Tom Chiller Sharon Chen Matthias Egger Simon Feys Jean-Pierre Gangneux Jeremy A W Gold Andreas H Groll Jannes Heylen Jeffrey D Jenks Robert Krause Katrien Lagrou Source Type: research
